Association of high mobility group box 1 protein with coronary artery disease

Abstract

Background

Recently, the role of inflammation in coronary artery disease and the association of inflammatory biomarkers with adverse outcomes have been investigated in many studies. We investigated the relationship between high serum mobility group box 1 protein levels and established risk factors for coronary artery disease.

Methods

Fifty-five patients who presented to our Cardiovascular Surgery Clinic and subsequently underwent coronary artery bypass surgery for coronary artery disease and 50 healthy subjects presenting to the cardiology outpatient clinic without any cardiovascular problem were included in the study. The mean age was 61.47 ± 9.38 years for patients and 58.20 ± 10.15 years for controls.

Results

There was no statistically significant difference between groups with respect to age or sex. Family history of coronary artery disease, aspirin use, hypertension, and type 2 diabetes were significantly more prevalent in the patient group versus the control group. A significant difference was found between patients and healthy controls with respect to high mobility group box 1 protein levels (p = 0.001).

Conclusions

Serum high mobility group box 1 protein was significantly increased in patients with coronary artery disease in comparison to healthy subjects. No associations were found between high mobility group box 1 protein level and certain risk factors for coronary artery disease.

Keywords

Coronary artery disease cytokines HMGB1 protein hyperlipidemias inflammation risk factors

Get full access to this article

View all access options for this article.

References

Hansson

GK.

Inflammation, atherosclerosis, and coronary artery disease.

N Engl J Med 2005; 352: 1685–1695.

Agharazii

St-Louis

Gautier-Bastien

et al . Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. Am J Hypertens 2015; 28: 746–755.

Jiang

Bai

et al . Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 2009; 406: 139–142.

Goodwin

Sanders

Johns

EW.

A new group of chromatin-associated proteins with a high content of acidic and basic amino acids.

Eur J Biochem 1973; 38: 14–19.

Stros

Polanská

Struncová

et al . HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II alpha. Nucleic Acids Res 2009; 37: 2070–2086.

Müller

Scaffidi

Degryse

et al . New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J 2001; 20: 4337–4440.

Thomas

Travers

AA.

HMG1 and 2, and related ‘architectural’ DNA binding proteins.

Trends Biochem Sci 2001; 26: 167–174.

Lotze

Tracey

KJ.

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.

Nat Rev Immunol 2005; 5: 331–342.

Scaffidi

Misteli

Bianchi

ME.

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Nature 2002; 418: 191–195.

10.

Klune

Dhupar

Cardinal

et al . HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476–484.

11.

Cai

Wen

Bauer

Zhong

Yuan

Chen

The Role of HMGB1 in cardiovascular biology: danger signals.

Antioxid Redox Signal 2015; 23: 1351–1369.

12.

Andrassy

Volz

Riedle

et al . HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 2011; 270: 245–253.

13.

Goldstein

Gallowitsch-Puerta

Yang

et al . Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571–574.

14.

Kohno

Anzai

Naito

et al . Role of high-mobility group box 1 protein in postinfarction healing process and left ventricular remodelling. Cardiovasc Res 2009; 81: 565–573.

15.

Kalinina

Agrotis

Antropova

et al . Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24: 2320–2325.

16.

Wang

Bloom

Zhang

et al . HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248–251.

17.

Libby

Ridker

Maseri

Inflammation and atherosclerosis.

Circulation 2002; 105: 1135–1143.

18.

Siasos

Tousoulis

Oikonomou

et al . Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des 2011; 17: 4132–4146.

19.

Jin

Zhao

Guo

Zhang

Chen

Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia.

Exp Ther Med 2012; 4: 1124–1126.

20.

Yin

Jin

Wang

Serum glycated albumin is superior to hemoglobin A1c for correlating with HMGB1 in coronary artery disease with type 2 diabetic mellitus patients. Int J Clin Exp Med 2015; 8: 4821–4825.